Vor Biopharma
About: Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
Employees: 168
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
300% more call options, than puts
Call options by funds: $28K | Put options by funds: $7K
100% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 2 (+1) [Q1 2025]
13% less funds holding
Funds holding: 52 [Q4 2024] → 45 (-7) [Q1 2025]
36% less capital invested
Capital invested by funds: $67.6M [Q4 2024] → $43.1M (-$24.5M) [Q1 2025]
40.62% less ownership
Funds ownership: 88.75% [Q4 2024] → 48.13% (-40.62%) [Q1 2025]
44% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 16
50% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 18
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
2,646%
upside
Avg. target
$6.33
3,378%
upside
High target
$8
4,293%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
JMP Securities Silvan Tuerkcan | 3,195%upside $6 | Market Perform Downgraded | 9 May 2025 |
Oppenheimer Matthew Biegler | 4,293%upside $8 | Outperform Reiterated | 21 Mar 2025 |
Stifel Stephen Willey | 2,646%upside $5 | Buy Maintained | 21 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing both near- and long-term shareholder value.
Neutral
GlobeNewsWire
2 months ago
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025 Anticipate initiation of the first trem-cel+VCAR33 Treatment System clinical trial in second half of 2025 $55.6 million private placement completed in December 2024 CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2024, and provided a business update.
Neutral
GlobeNewsWire
4 months ago
Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials
Clinical trial complexity, logistical challenges associated with treatments, and resource constraints at trial sites cited as top factors that delay enrollment into cell and gene therapy (CGT) clinical trials Despite the increased time required to obtain informed consent, 100% of those surveyed continue to offer patients these innovative investigational treatment options CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today presented novel research evaluating the patient experience and barriers to enrollment and participation in cell and gene therapy (CGT) trials.
Neutral
GlobeNewsWire
4 months ago
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference
CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Oppenheimer's 35th Annual Healthcare Life Sciences Conference.
Positive
Zacks Investment Research
4 months ago
Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross
Vor Biopharma Inc. (VOR) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VOR's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Neutral
GlobeNewsWire
5 months ago
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors
CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of Directors. The appointment represents a new seat on Vor Bio's Board of Directors, which has been created in connection with the recent private investment in public equity financing (PIPE) which was led by Reid Hoffman. Mr. Kalir will serve as the director designee of Reprogrammed Interchange, LLC, Mr. Hoffman's investment fund.
Neutral
GlobeNewsWire
5 months ago
Vor Bio Announces $55.6 Million Private Placement
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33 ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg in the second half of 2025
Neutral
GlobeNewsWire
6 months ago
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced updated clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data, which was presented in a poster at the American Society of Hematology (ASH) Annual Meeting on Sunday, December 8th, demonstrated durable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of improved relapse free survival compared to published high-risk AML comparators.
Neutral
GlobeNewsWire
8 months ago
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new Chief Financial Officer, effective immediately. Dr. Choi will join the Vor Bio leadership team and will report directly to the company's President and Chief Executive Officer, Dr. Robert Ang.
Positive
Benzinga
9 months ago
What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?
Thursday, Vor Biopharma Inc. VOR announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory acute myeloid leukemia (AML) receiving trem-cel followed by Mylotarg.
Charts implemented using Lightweight Charts™